Showing results (1-10 of 86) with videos related to
Sort By:
Pageof 9
Expert Review of Anticancer Therapy|February 25, 2003
Gemcitabine in transitional cell carcinoma of the urotheliumHans von der MaaseOncology (Williston Park, N.Y.)|January 20, 2005
Pemetrexed in transitional cell carcinoma of the urotheliumHans von der MaaseSeminars in Oncology|March 15, 2002
Current and future perspectives in advanced bladder cancer: is there a new standard?Hans von der MaaseJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Impact of immune parameters on long-term survival in metastatic renal cell carcinomaFrede Donskov, Hans von der MaaseActa Oncologica (Stockholm, Sweden)|March 15, 2005
Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancerLars Fokdal, Morten Høyer, Hans von der MaaseExpert Review of Anticancer Therapy|February 1, 2006
Radical radiotherapy for urinary bladder cancer: treatment outcomesLars Fokdal, Morten Høyer, Hans von der MaaseActa Oncologica (Stockholm, Sweden)|September 18, 2008
Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapyChristian Jessen, Mads Agerbaek, Hans Von Der MaaseActa Oncologica (Stockholm, Sweden)|September 14, 2007
Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?Anne Birgitte Als, Lisa Sengelov, Hans Von Der MaaseUgeskrift for Laeger|June 27, 2002
[Three cases of thrombosis of the internal jugular vein]Jens Fuglsang, Lars Ulrik Fokdal, Hans von der MaaseEuropean Urology|March 27, 2007
Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategiesAnne Birgitte Als, Lisa Sengelov, Hans von der MaasePageof 9